Cyclin-dependent kinases (Cdk) and their associated pathways represent some of the most attractive targets for the development of anticancer therapeutics. Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clinical evaluation either as a single agent or in combination with other approved drugs. In our anticancer drug discovery program, a novel series of flavones have been synthesized for evaluation against the activity of Cdk4-D1. This enzyme catalyzes the phosphorylation of retinoblastoma protein, thus inhibiting its function. We have identified a series of potent Cdk4-D1 inhibitors with IC 50 below 250 nmol/L. In this report, we have described the properties of one of the best compound,
Introduction
The ability of eukaryotic cells to proliferate in response to a growth signal is tightly controlled by a complex network of ordered biochemical events collectively known as the cell cycle (1 -3) . The cell cycle can be divided into four phases: G 1 (Gap1) during which cellular events are preparing the cell for DNA synthesis; S (Synthesis) phase in which DNA replication occurs; G 2 (Gap2), preparing the cell for division; and M (Mitosis), which is the effective division of the mother cell into two daughter cells (3) . Cyclindependent kinases (Cdk) are critical regulators of cell cycle progression and are constitutively expressed throughout the cell cycle (3) . Expression and interaction of Cdks, cyclins, and their activators and inhibitors, account to a great extent for the timing of events in cell cycle. Specific Cdks operate in distinct phases of the cell cycle. The major regulatory checkpoint in this process controls the transition from G 1 to S phase and is characterized by inactivation and phosphorylation of the retinoblastoma (Rb) gene product (4) . Inactivation of Rb leads to the release of the transcriptional factor E2F1 and the activation of E2F-responsive genes necessary for progression to S phase (5 -8) . Complexed with their respective D-type cyclins, Cdk4 and Cdk6 are responsible for the progression of the cells through G 1 (9 -11) . A complex of Cdk2 and cyclin E is required for the progression of the cells from G 1 to S phase.
A single, most defining feature of cancer is unchecked growth. In malignant cells, altered expression of Cdks and their modulators, including overexpression of cyclins and loss of expression of natural Cdk inhibitors, results in deregulated Cdk activity, providing a selective growth advantage (12 -14) . Because of their critical role in cell cycle progression, as well as the association of their activities with the processes of differentiation and apoptosis, the Cdks comprise an attractive set of targets for novel antineoplastics.
Several drug discovery programs have produced potent small-molecule Cdk inhibitors (15 -20) . A variety of chemical classes, which include purine analogues (21 -25) , pyrimidine analogues (26) (27) (28) , indenopyrazoles (29, 30) , pyridopyrimidines (31) (32) (33) , pyrazolopyridines (34, 35) , indolocarbazoles (36) , pyrrolocarbazoles (37, 38) , oxindoles (39, 40) , and aminothiozoles (41) have been developed as Cdk inhibitors. Several compounds that inhibit Cdk activity are currently in clinical trials, including flavopiridol, R-roscovitine (CYC-202), UCN-01 (7-hydroxystaurosporine), and BMS-387032 either as single agents or in combination. Most of these compounds, however, inhibit multiple Cdks, with Cdk2 being a particularly common target. The present report describes a potent inhibitor of Cdk4-D1, Cdk1-B, and Cdk9-T1 with f40-fold selectivity over Cdk2-E in in vitro enzyme assays. Furthermore, we describe the antiproliferative activity of this compound in a broad spectrum of human cancer cell lines. We also provide evidence of down-regulation of cyclin D1 and Cdk4 protein levels with decreased phosphorylation of pRb at Ser 780 , an event that was preceded by the loss of Cdk4-D1 activity. The ability of the compound to induce apoptosis and the effect on Cdk4-D1 enzyme kinetics were also studied.
Materials and Methods
Compound Used for the Studies Compounds P276-00 and flavopiridol were synthesized at Nicholas Piramal Research Centre, Nicholas Piramal India Limited, Mumbai, India.
Cell Lines and Cell Culture Conditions All human cancer cell lines were obtained either from the American Type Culture Collection (Manassas, VA) or from National Centre for Cell Sciences, Pune, India. Cells were maintained in the appropriate media such as RPMI 1640, DMEM, McCoy's or F12 K Hams modified medium supplemented with fetal bovine serum, 2 mmol/L L-glutamine, and penicillin (100 units/mL) and streptomycin (10 units/ mL) in a humidified 37jC incubator with 5% CO 2 .
Cdk4-Cyclin D1 and Cdk2-Cyclin E Enzyme Assays Human cyclin-dependent kinase-4/2 was coexpressed with cyclin D1/E in a baculovirus expression system. To accomplish this, 1 Â 10 7 Sf9 cells were coinfected with baculoviruses containing human glutathione S-transferase (GST) -tagged Cdk-4/2 and cyclin D1/E genes. The cells were lysed after 72 h in 500 AL of the lysis buffer [50 mmol/ L HEPES (pH, 7.5), 10 mmol/L MgCl 2 , 1 mmol/L DTT, 5 Ag/mL of aprotinin, 5 Ag/mL of leupeptin, 0.1 mmol/L NaF, 0.2 mmol/L phenylmethylsulfonyl fluoride, and sodium orthovanadate]. The cell lysate was centrifuged, and the supernatant was purified on a GST-sepharose column. Purity of the proteins was checked by SDS-PAGE followed by Western blots using antibodies specific to Cdk4 or Cdk2 (Santa Cruz Biotechnology, Santa Cruz, CA).
GST-retinoblastoma (amino acids 776 -928) fusion protein was expressed in Escherichia coli and purified by reduced glutathione (GSH)-Sepharose affinity chromatography. GST-Rb bound to these beads served as the substrate in the assay.
The Cdk4-D1/Cdk2-E enzyme assay was run in 96-well format using Millipore Multiscreen filtration plates (Unifilter plates, Packard, Meriden, CT). All assay steps are done in a single filter plate. The filtration wells were prewetted with 100 AL of kinase buffer [ Other In vitro Kinase Assays for Specificity Analysis In vitro kinase assays in the presence of increasing concentrations of P276-00 and appropriate substrates were carried out using a Kinase Profiler (Protocol Guide) at Upstate (Dundee, United Kingdom).
In vitro Cell Proliferation Assay Exponentially growing cultures of human cancer cell lines were used to assess the effect of compounds on proliferation and survival. All the compounds showing IC 50 V 1 Amol/L in Cdk4-D1 enzyme assay were evaluated in the in vitro cell proliferation 3 H-thymidine uptake assay. The cells were seeded at a density of 3,000 -5,000 cells per well, depending on cell type in 180 AL of culture medium in 96-well plate and incubated overnight to allow the cells to adhere. Varying concentrations of compounds were added to the wells and incubated for 48 h at 37jC. 3 H-thymidine (0.25 ACi) was added to each well, and incorporation of the radiolabel was allowed to proceed for 5 to 7 h. Following this incubation, cells were harvested onto GF/B unifilter plates (Packard) using a Packard Filtermate Universal harvester, and the plates were counted in a Packard Top Count 96-well liquid scintillation counter.
Immunoprecipitation H-460 and MCF-7 cells were treated with 1.5 Amol/L P276-00 for 3, 6, 9, 12, and 24 h. Following this incubation, the cells were lysed in chilled cell lysis buffer [50 mmol/L HEPES (pH, 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 2.5 mmol/L EGTA, 1 mmol/L DTT, 0.1% Tween 20, 10% glycerol, 0.1 mmol/L phenylmethylsulfonyl fluoride, 100 Ag/mL leupeptin, 20 Ag/mL aprotinin, 10 mmol/L h-glycerphosphate, 1 mmol/L NaF, and 0.1 mmol/L sodium vanadate]. The cell lysate was cleared by centrifugation at 10,000 Â g for 15 min at 4jC. Cdk4 was immunoprecipitated using specific Cdk4 antibody (Santa Cruz Biotechnology) with protein A-sepharose beads at 4jC from 400 Ag protein from cell lysates. The immune complexes were washed thrice with NET-N [20 mmol/L Tris-HCl (pH, 7.5), 100 mmol/L NaCl, 1 mmol/L EDTA, and 0.5% NP40] and twice with kinase buffer. Kinase assay was then done as described in the method above using this immune complex and the Rb protein as a substrate.
Western Blot Analysis H-460 and MCF-7 cells were treated with P276-00 at 1.5 Amol/L for 3, 6, 9, 12, and 24 h. HL-60 cells were treated with 0.5, 1.0, 2.5, and 5.0 Amol/L concentrations of P276-00 for 6 and 24 h. Cells were lysed, and protein content of the lysate was estimated using the Bradford reagent. An equal amount of protein was loaded on SDS-PAGE, and Western blot analysis was carried out as described previously (42) using specific antibody to cyclin D1, Cdk4, pRb, and phospho-pRb Ser 780 antibodies (Santa Cruz Biotechnology) for H-460 and MCF-7 cell lysate. Similarly, specific antibody to cleaved caspase-3 (Santa Cruz Biotechnology) was used for HL-60 cell lysate.
Caspase-3 Cellular Activity HL-60 (human promyelocytic leukemia) cells were treated with different concentrations of P276-00 for 24 h and lysed, and the lysate was assayed using the caspase-3 cellular activity kit (Calbiochem, La Jolla, CA).
DNA Ladder Formation HL-60 cells were treated with different concentrations of P276-00 for 24 and 48 h. Cells were lysed, and DNA was isolated and subjected to 1.5% agarose gel electrophoresis as described previously (43) .
Quantitation of DNA Fragmentation The amount of DNA fragmentation was quantified using the method of Xia et al. (44) . This method separates fragmented and genomic DNA and stains it with DNA intercalating fluorescent dye, 4 ¶-6-diamidino-2-phenylindole. Excitation at 365 nm and emission at 454 nm were read using a Flurometer (POLARstar Optima from BMG, Labtach GmbH, Offenburg, Germany).
Enzyme Kinetic Studies Cdk4-D1 kinase activity was measured by varying the concentrations of Rb 200 Ag/mL (1, 2, 4, 6, 8, and 10 AL) or ATP (10, 30, 50, 70 , 100, and 150 Amol/L) as substrates in the presence of different concentrations of P276-00 (30, 60, and 90 nmol/L). The Cdk4-D1 assay was carried out as described above. The enzyme inhibitory activity of P276-00 was determined by measuring the phosphorylation of Rb in comparison with the absence of inhibitors.
Results

Inhibition of Cdk4-D1 and Cdk2-E Enzyme Activity
In an effort to generate novel anti-Cdk4 inhibitors, several flavone derivatives (Fig. 1) were evaluated for their in vitro kinase activity as part of the anticancer-screening program. Several compounds exhibiting below 200 nmol/L in vitro anti-Cdk4 activity were selected. Optimization of the leads with structure-activity relationship studies yielded the most potent compound P276-00 with an IC 50 of 63 F 18.5 nmol/L in Cdk4-D1 enzyme assay. This compound was then screened for inhibition of Cdk2 activity. The results of these experiments confirmed that P276-00 exhibited the highest potency and selectivity for Cdk4-D1 in comparison with Cdk2-E ( Table 1) . For Cdk4-D1 and Cdk2-E enzyme assays, flavopiridol is used as standard and showed IC 50 of 40 F 15 and 150 F 50 nmol/L, respectively.
Selectivity of P276-00 against Different Kinases To ascertain the selectivity of P276-00 for cyclin-dependent and non-Cdks, it was tested against a panel of Cdks and kinases other than Cdks by performing in vitro kinase assays in the presence of increasing concentrations of P276-00 and the appropriate substrates as per the Kinase Profiler at Upstate (Table 1) . P276-00 exhibited greater selectivity (IC 50 s below 100 nmol/L) to Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks tested. P276-00 showed the highest potency for Cdk9-T1 with an IC 50 of 20 nmol/L. When compared with other Cdks that are directly involved in cell cycle progression, it was found to be more selective for Cdk4-D1 and Cdk1-B inhibition than Cdk2-E and Cdk7-H (f40 times specific for Cdk4-D1). In addition, it was not active against many non-Cdk enzymes such as mitogen-activated protein kinase 1 (MAPK1), MAPK2, PKCa, PKA, PKC, LCK, and GSK3h and cSRC (Table 1) .
Potency against HumanTumor Lines
Based on the potency in in vitro Cdk4-D1 enzyme assay, P276-00 was selected as the best compound for further studies. Its antiproliferative effect was also determined in a panel of 12 tumor cell lines in comparison with two normal fibroblast cell lines using the 3 H-thymidine uptake assay. The range of IC 50 values for the cell line panel spanned from 300 to 800 nmol/L in the 3 H-thymidine uptake assay. To ascertain whether the compound had any selectivity for normal versus cancer cells, human normal lung fibroblast WI-38 and MRC-5 were treated with P276-00. The IC 50 value for normal fibroblast cell lines was significantly higher than those obtained for human tumor cell lines ( Table 2) .
Loss of Cdk4 Activity Induced by P276-00 Precedes Depletion of Cyclin D1, Cdk4, and Rb Hypophosphorylation Cdks, their activators, and natural inhibitors are responsible for the regulation of the cell cycle. Cell homeostasis is Figure 1 . General structure of P276-00 series of flavones.
Novel Cdk Inhibitor maintained as long as these factors are in the right proportions. Deregulation of these proteins may lead to cancer. P276-00 was studied for its effect on the regulation of levels of cell cycle proteins in human non -small cell lung cancer (H-460) and human breast cancer (MCF-7) cell lines. To address whether P276-00 decreases the abundance of cyclin D1 indirectly because of effects on G 1 Cdk function, catalytic Cdk4 enzyme activity was measured from intact H-460 and MCF-7 cell lines exposed to P276-00. Cdk4 kinase activity immunoprecipitated from growing MCF-7 and H-460 cells following exposure to 1.5 Amol/L P276-00 for various times is shown in Fig. 2 . Shortly after addition of P276-00 to H-460 cells (3, 6, 9, 12 , and 24 h), significant reduction in enzyme activity was seen at 6 h onward (Fig. 2) . This decline in Cdk4-D1 activity in H-460 was followed by a reduction in cyclin D1, Cdk4, and Rb levels as seen by Western blot analysis (Fig. 3A) . However, decrease in Rb phosphorylation at Ser 780 was seen at 3 h itself (Fig. 3A) . Similar treatment of MCF-7 cells shows a loss in Cdk4-D1 enzyme activity at 3 h onward (Fig. 2) , whereas protein levels of cyclin D1 and Cdk4 levels starts decreasing at 6 and 9 h, respectively (Fig. 3B) . This was also accompanied by a decrease in phosphorylation of Rb at Ser 780 from 6 h onward, followed by reduced Rb levels at 24 h (Fig. 3B) . Therefore, from these results, it seems that the loss of Cdk4-D1 activity at the early time point is not due to the specific decline in cyclin D1 and Cdk4 levels. Instead, loss of Cdk4 activity precedes cyclin D1 and Cdk4 depletion. Caspase-3 CellularActivity andWestern Blot Analysis Caspase-3, an executioner caspase, is activated during apoptotic signaling events by upstream proteases, including caspase-6, caspase-8, and cytotoxic T cell -derived granzyme B. Caspase-3 is one of the principal caspases found in apoptotic cells. Hence, the ability of P276-00 to induce caspase-3 activity in HL-60 cells was examined. HL-60 cells were treated with 0.5, 0.75, and 1 Amol/L of P276-00 for 24 h. Actinomycin, a known inducer of apoptosis, was used as a positive control. As compared with untreated control, a dose-dependent increase was seen in cellular caspase-3 activity after 24 h of treatment with P276-00 (Fig. 4) . The specific activity of caspase-3 at 0.5, 0.75, and 1 Amol/L of P276-00 were 17.2, 116.5, and 138.2 pmol/min/Ag, respectively. The caspase activity increases from 3.6-to 29-fold over the control activity of 4.763 pmol/ min/Ag. Western blot analysis of caspase-3 protein using cleaved caspase-3 -specific antibody indicates an increase in the levels of cleaved caspase-3 after 24 h of treatment with P276-00 (Fig. 5) .
DNA Ladder Formation
During apoptosis, cells undergo widespread morphologic changes (chromatin condensation and cytoplasmic blebbing), which is associated with the incidence of nucleosome excision from chromatin. This endonucleasemediated nucleosome excision is observed as a DNA ladder (multimers of f180-200 bp) in agarose gels. This characteristic form of DNA degradation is a major biochemical hallmark of apoptosis. HL-60 cells treated with 1 Amol/L of P276-00 for 24 h and 2.5 Amol/L for 24 and 48 h induced apoptosis as evident by the DNA ladder formation (Fig. 6) .
Quantitation of DNA Fragmentation HL-60 (promyelocytic leukemia) cells treated with 0.25, 0.5, and 0.75 Amol/L of P276-00 for 48 h showed increase in apoptosis from 30% to 80% at 48 h with increasing concentration of P276-00 (Fig. 7) . The induction of DNA fragmentation was also compared with the normal lung fibroblast cell line WI-38 versus the cancerous non -small cell lung carcinoma cell line H-460. H-460 cells showed 85% and 73% apoptosis at 2.5 and 5.0 Amol/L, respectively, as compared with 5% apoptosis in the normal cell line at 5.0 Amol/L of P276-00 (Table 3) . These results further confirm our previous observations that P276-00 is not active in the normal fibroblast cell line.
Kinetics of Inhibition of Cdk4-D1 by P276-00
In an attempt to study the role of P276-00 with respect to Cdk4 inhibition, enzyme kinetics was studied. The enzyme kinetics (competitive, uncompetitive, or mixed type) was determined from inhibition measured against varying concentrations of one substrate (Rb or ATP) and fixed concentration of the other substrate. As seen from the Lineweaver-Burk plot (45) , V max remains constant with increasing concentration of ATP, indicating that P276-00 is a competitive inhibitor with respect to ATP (Fig. 8A) . In the case of Rb at varying concentrations of the inhibitor, all have the same slope, indicating a proportional decrease in the value of K m and V max . This indicates that it is an uncompetitive inhibition relative to Rb (Fig. 8B ).
Discussion
It is well established that eukaryotic cell proliferation is a tightly regulated system controlled by a network of cyclinCdk complexes (46 -48) . In epithelial cells, the major regulatory checkpoint in this process is the transition from G 1 to the S phase. This transition is characterized by the phosphorylation of pRb, and the Cdk4-D1 enzyme complex catalyzes the reaction. Because most carcinomas are of epithelial origin, they exhibit a general dependence on Cdk4-D1 activity for their proliferation. Inhibition of Cdk4-D1 results in the inhibition of cell proliferation as evidenced by the experiments using antisense or antibodies to cyclin D1 (49 -53) . These observations suggest that an agent that can block the activity of this enzyme complex may be of therapeutic value against most carcinomas.
In this study, we report the results of our efforts to find inhibitors of Cdks and their possible therapeutic utility. We identified potent compounds from a series of synthetic flavones screened in an in vitro Cdk4-D1 enzyme assay. The best compound P276-00 was profiled. To establish the selectivity of P276-00, it was tested against a representative panel of serine, threonine, and tyrosine kinases. It potently inhibited Cdk9-T1 enzyme activity, which is a known transcription activator. Other than potent activity IC 50 below 100 nmol/L in Cdk4-D1, Cdk1-B, and Cdk9-T1, the compound had little or no activity against other Cdks and non-Cdks. These in vitro enzyme assay results also suggested that the compound P276-00 would be the most potent inhibitor of cell proliferation. It was further tested in cell proliferation assay, i.e., 3 H-thymidine uptake assay in a panel of 12 cancerous cell lines and two normal fibroblast cell lines. We were able to show a selective antitumor effect, with an average potency of 568 nmol/L against a panel of human tumor cell lines, that compared with potency of almost 5-fold or higher against nonproliferating cells, suggesting that a therapeutic window could be achieved because they might have a selective cytotoxic effect on rapidly proliferating cells over quiescent or slowly proliferating normal cells, a property that would make them suitable for use in anticancer therapies.
With P276-00 being a potent Cdk4-D1 inhibitor, the cellular levels of cyclin D1, Cdk4, Rb, and phospho-Rb Ser 780 were investigated. The phosphorylation mediated by Cdk4 on Rb protein is required for the cells to progress from G 1 to S phase in those cells possessing a functional phospho-Rb. As an indication of P276-00 inhibiting the Cdk4 within the cells, we have determined the phosphorylation status of Rb gene product following exposure to P276-00 in exponentially growing H-460 and MCF-7 cells. Over a 24-h exposure to P276-00 in both the cell lines, we found that Cdk4 enzyme activity is inhibited as seen by immunoprecipitation (Fig. 2) . This is also confirmed by Western blot, which shows that the Rb protein changed from mostly hyperphosphorylated pRb at 3 h in H-460 and at 6 h in MCF-7 cells to a completely dephosphorylated form at 24 h (Fig. 3) . In this study, we show that P276-00, a potent Cdk inhibitor, induces a decline in cyclin D1 and Cdk4 levels. The depletion of cyclin D1 and Cdk4 is preceded by the loss of Cdk4-D1 activity and Rb phosphorylation, thus indicating that the P276-00 may exert its antiproliferative effect at an early stage through inhibition of Cdk4-D1 in a competitive manner with ATP. This evidence is also provided by enzyme kinetic studies, which show that P276-00 competes with ATP for binding at the catalytic site of the Cdk4 enzyme and, thus, inhibiting its kinase activity. Alternatively, inhibition of Cdk9-T1 globally affects cellular transcription with the most profound effects on synthesis of mRNA with short lives, including those encoding growth and apoptosis regulators. Effect of Cdk9-T1 may underline the transcriptional repression of cyclin D1 by P276-00 as seen in flavopiridol (54, 55) , which needs to be proven. To define the mechanism by which P276-00 induces cell death, caspase-3 cellular activity, DNA ladder formation and quantitation of DNA fragmentation were studied. The results showed that caspase-3 activity increased with increasing concentrations of P276-00. This was further confirmed by demonstrating DNA ladder formation, a biochemical hallmark of apoptosis. Western blot analysis also indicated the increase in caspase-3 protein levels as an executioner protein for apoptosis. Apoptotic DNA was quantitated using the fluorescent dye 4 ¶-6-diamidino-2-phenylindole. An increase in apoptotic DNA was seen on treatment of the cells with P276-00. These results showed that the antiproliferative effect of P276-00 is through the induction of apoptosis in tumor cell lines. The enzyme kinetic studies indicate that P276-00 is a competitive inhibitor of Cdk4-D1 enzyme and competes with ATP for the ATP binding site on the enzyme. P276-00, like flavopiridol, belongs to the flavone class of compounds. However, unlike flavopiridol, it shows better selectivity toward Cdk1-B, Cdk4-D1, and Cdk9-T1 as compared with Cdk7-H and Cdk2-E. It inhibits Cdk4-D1, Cdk9-T1, and Cdk1-B with almost the same potency as flavopiridol. However, the inhibition of tumor cell growth in culture is twice to thrice higher than flavopiridol, which may be attributed to its not being a potent pan-Cdk inhibitor and, hence, is also less toxic than flavopiridol (56) , although in comparison to other Cdk inhibitors like kenpaullone, olomoucin, and roscovitine, P276-00 is substantially more potent in inhibiting tumor cell growth in culture.
The results presented in this paper show that Cdks are a viable target for anticancer therapy. By focusing on specific mechanisms of tumorigenesis, we have developed a primary screening assay for discovering compounds that may be developed for cancer chemotherapy. We have also illustrated that it is necessary in this process to incorporate both in vitro enzyme and cell-based proliferation assays to evaluate compounds for their therapeutic potential. Predictive evaluations of potency and efficacy in cell systems and/or in animal models are essential adjuncts to primary screening in the drug discovery process. Compound P276-00, a novel Cdk inhibitor, is currently in phase I/II clinical trials. Outcome of clinical trial results will decide the beneficial effects of Cdk inhibitors. 
